Heterocyclic Compounds

Matches 251 - 300 out of 15,438	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/180189A1	MPRO TARGETING ANTIVIRAL COMPOUNDS Disclosed are novel viral Mpro inhibitors according to Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to inhibit Mpro and...
WO/2023/183540A1	IKZF2 DEGRADERS AND USES THEREOF Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
WO/2023/179600A1	NOVEL SUBSTITUTED MACROHETEROCYCLIC COMPOUNDS AND USE THEREOF Disclosed in the present invention are novel substituted macroheterocyclic compounds, which can be used as inhibitors for targets such as ALK mutations, or ALK mutation related signaling pathways, for example NTRKs, ROS1, BRAF, c-MET, EG...
WO/2023/182835A1	ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME The present invention relates to a novel organic compound and an organic electroluminescent element using same, and more specifically, to a compound having excellent electron injection and transport capabilities, and an organic electrolu...
WO/2023/178452A1	ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful...
WO/2023/173651A1	METHOD FOR SYNTHESIZING CHIRAL SPIRO-TETRAHYDROFURAN-PYRAZOLONE COMPOUND Disclosed in the present invention is a method for synthesizing a chiral spiro-tetrahydrofuran-pyrazolone compound, specifically comprising: taking vinyl cyclic carbonate and α,β-unsaturated pyrazolone as reactants, Pd(PPh3)4 as a meta...
WO/2023/174409A1	SALT FORM AND CRYSTAL FORM OF VANIN ENZYME INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention relates to a salt form and a crystal form of a Vanin enzyme inhibitor represented by formula I, a method for preparing same, and use thereof. The salt form is a salt formed by the compound represented by formula I w...
WO/2023/174175A1	KIF18A INHIBITOR A type of KIF18A inhibitor. Specifically provided are a compound represented by general formula (1), a preparation method therefor, and an isomer, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a ...
WO/2023/178302A1	PARTHENOLIDE DERIVATIVES AND USE THEREOF Natural product-like compounds are derived from the sesquiterpene lactone parthenolide. Methods are provided for the generation of novel natural product-like molecules obtained through the chemoenzymatic reelaboration and modification of...
WO/2023/170699A1	TRICYCLIC SPIRO[CHROMANE-2,4'-PIPERIDIN]-4(3H)-ONE WITH 1,3,4-OXADIAZOLE LINKERS COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF. The present invention describes tricyclic spiro [chromane-2,4-piperidin]-4(3H)-one with 1,3,4-oxadiazolederivatives of general formula X : Wherein, independently for each occurrence: 0 R is H, Br R' is OH or O A is Wherein B1, B2, B3 and...
WO/2023/168686A1	SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
WO/2023/173083A1	TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER This disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt that inhibits epidermal growth factor receptor (EGER, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These compounds of formu...
WO/2023/169226A1	SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Provided are substituted tricyclic compounds as PARP inhibitors and the use thereof. The compounds represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L and Cy are defined herein. The compounds of Fo...
WO/2023/172415A1	SWEETENER COMPOSITIONS Described herein are compounds useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described. (I)
WO/2023/172069A1	ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention relates to a novel compound with a characteristic structure and a high-efficiency, long-lifetime organic light-emitting device including same as a host compound in the light-emitting layer. Employing a polycyclic co...
WO/2023/165438A1	TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to a substituted tricyclic derivative, a preparation method therefor, and pharmaceutical use of a pharmaceutical composition comprising same. Specifically, the present invention relates to a substituted tric...
WO/2023/166883A1	COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT This organic light-emitting element in which a compound represented by the general formula is used exhibits excellent light-emitting characteristics. In the general formula, one or two of R1-R4 are fused-ring carabazol-9-yl groups, at le...
WO/2023/160112A1	AZAPHILONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS Provided is a use of an azaphilone compound of formula (I) in the preparation of drugs for treating or preventing diseases, including but not limited to tumors, autoimmune diseases, infectious diseases and aging, and a method for treatin...
WO/2023/161168A1	AROMATIC HETREOCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES The present invention relates to aromatic heterocycles that are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
WO/2023/163479A1	ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
WO/2023/164612A1	MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN Disclosed herein are compounds (I) and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of d...
WO/2023/156565A1	BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds u...
WO/2023/159087A1	QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula (I): (Formula (I)) wherein the variables of Formula (I) are defined herein. This disclosure ...
WO/2023/155927A1	INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...
WO/2023/158862A2	STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF The invention provides novel modulators of STING (Stimulator of Interferon Genes) and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as cancer, in...
WO/2023/159086A1	QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula I : (I) wherein the variables of Formula I are defined herein. This disclosure also provides...
WO/2023/150899A1	CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF Novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions.
WO/2023/151642A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure, wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2023/152063A1	MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, particularly organic electroluminescent devices, containing these compounds.
WO/2023/154905A1	ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compoun...
WO/2023/153739A1	NOVEL COMPOUND AND USES THEREOF The present invention relates to a novel compound and uses thereof and, more specifically, to a compound capable of labeling a biomolecule (e.g. nucleic acid, protein, etc.), a composition for labeling or detecting a biomolecule comprisi...
WO/2023/154499A1	EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
WO/2023/154962A1	CGAS INHIBITORS AND USES THEREOF The disclosure relates generally novel inhibitors of human cGAS and methods of treating cGAS -related diseases or disorders in a patient.
WO/2023/151513A1	CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF The invention provides novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions (e.g., cancer).
WO/2023/153844A1	HETEROCYCLIC COMPOUND, AND COMPOSITION FOR FORMING ORGANIC LIGHT-EMITTING ELEMENT AND ORGANIC MATERIAL LAYER COMPRISING SAME The present specification relates to a heterocyclic compound of chemical formula 1, and a composition for forming an organic light-emitting element and an organic material layer, wherein the composition comprises the heterocyclic compound.
WO/2023/152346A1	MATERIALS FOR ELECTRONIC DEVICES The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
WO/2023/154519A1	INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
WO/2023/154314A1	SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
WO/2023/150056A1	PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula (A), as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein ...
WO/2023/150776A1	WATER-SOLUBLE HETEROCYCLYL POLYMETHINE CHROMOPHORES The present disclosure provides water-soluble and low-aggregation NIR- and SWIR- active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.
WO/2023/150681A1	INHIBITORS OF RAF KINASES Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
WO/2023/147149A1	ANHYDROUS CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETA MIDE Provided is an anhydrous crystalline form of Pelabresib as well as its use for treating conditions associated with BET proteins.
WO/2023/141705A1	USE OF CEPHARANTHINE AND A TAXANE IN THE TREATMENT OF PROSTATE CANCER The present disclosure relates to the treatment of prostate cancer using a combination of cepharanthine or a pharmaceutically acceptable salt thereof, and a taxane, optionally paclitaxel, docetaxel, or cabazitaxel. Also described herein ...
WO/2023/143154A1	PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF Disclosed are a pharmaceutical composition, a method for preparing same, and use thereof. The composition comprises the following components: an antibody-drug conjugate, a buffer system, a lyoprotectant, and a surfactant. The pharmaceuti...
WO/2023/146990A1	COMPOUNDS AND METHODS OF USE Provided are compounds of Formula (A) and Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, RB, Ring B, R1, R2 and n ...
WO/2023/144559A1	ANTAGONIST OF ADENOSINE RECEPTORS The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
WO/2023/143208A1	PREPARATION METHOD FOR DRUG LINKER CONJUGATE The present invention provides a preparation method for a drug linker conjugate. The present invention further provides a preparation method for an intermediate or a salt thereof, and a use of an intermediate or a salt thereof. The raw m...
WO/2023/143393A1	TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a tricyclic compound, and a preparation method therefor and the use thereof. The tricyclic compound has a structure as shown in formula I, and can be used for treating various mental diseases and neurodegenerative diseases ...
WO/2023/144160A1	NEW HETEROCYCLIC COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
WO/2023/143623A1	QUINOLINE COMPOUND AND USE THEREOF Disclosed are a quinoline compound and the use thereof. The quinoline compound is a compound as represented by formula (I), formula (II) or formula (III), a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer ther...

Matches 251 - 300 out of 15,438	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >